A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation

Trial Profile

A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Olmutinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 02 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by Clinicaltrials.gov record.
    • 02 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
    • 19 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top